High Level of Anaphylatoxin C5a Predicts Poor Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma

Overview

Journal Sci Rep

Specialty Science

Date 2016 Jul 7

PMID 27381421

Citations 13

Authors

Wei Xi

Li Liu

Jiajun Wang

Yu Xia

Qi Bai

Qilai Long

Yiwei Wang

Jiejie Xu

Jianming Guo

Affiliations

Soon will be listed here.

Abstract

Anaphylatoxin C5a, a potent pro-inflammatory peptide produced in the process of complement activation, was proved to have a vital role in tumor initiation and progession by previous investigations. However whether it could act as a prognostic marker remains unknown. Here we retrospectively enrolled 272 ccRCC patients undergoing nephrectomy in Zhongshan Hospital, Shanghai between 2005 and 2007. C5a level was assessed by immunohistochemistry and its association with clinicopathologic features and prognosis were evaluated. Our results indicated that high tumoral C5a level was associated with poor overall survival (OS) (hazard ratio = 1.753, 95% CI 1.068-2.878, P = 0.026). In addition, tumoral C5a could significantly stratify patients' prognosis both in advanced stage (TNM III + IV) and intermediate/high risk group (SSIGN score ≥4) (P < 0.001 and = 0.008, respectively). Furthermore, incorporating tumoral C5a with other parameters could improve the predicting accuracy, compared with TNM and SSIGN system (c-index = 0.789, 0.713 and 0.727, respectively). In conclusion, tumoral C5a is an independent adverse prognostic biomarker for clinical outcome of ccRCC patients after nephectomy.

Citing Articles

Plasma proteome fingerprint in kidney diseases.

Nikolsky K, Kopylov A, Nakhod V, Potoldykova N, Enikeev D, Butkova T Front Mol Biosci. 2025; 11:1494779.

PMID: 39896931 PMC: 11782039. DOI: 10.3389/fmolb.2024.1494779.

The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice?.

Panebianco M, Ciccarese C, Strusi A, Beccia V, Carbone C, Agostini A Cancers (Basel). 2024; 16(3).

PMID: 38339243 PMC: 10854780. DOI: 10.3390/cancers16030490.

A novel prognostic N-methylguanosine-related long non-coding RNA signature in clear cell renal cell carcinoma.

Luo W, Lu J, Zheng X, Wang J, Qian S, Bai Z Sci Rep. 2023; 13(1):18454.

PMID: 37891201 PMC: 10611723. DOI: 10.1038/s41598-023-45287-w.

The Preoperative Serum Levels of the Anaphylatoxins C3a and C5a and Their Association with Clinico-Pathological Factors in Breast Cancer Patients.

Hameed B, Abdulsatar Al-Rayahi I, Muhsin S Arch Razi Inst. 2023; 77(5):1873-1879.

PMID: 37123148 PMC: 10133588. DOI: 10.22092/ARI.2022.358193.2173.

By Increasing the Expression and Activation of STAT3, Sustained C5a Stimulation Increases the Proliferation, Migration, and Invasion of RCC Cells and Promotes the Growth of Transgrafted Tumors.

Zheng J, Zhou H, Yu H, Xia Y, Yu Q, Qu H Cancer Manag Res. 2021; 13:7607-7621.

PMID: 34675657 PMC: 8500505. DOI: 10.2147/CMAR.S326352.

References

Athar U, Gentile T . Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008; 15(2):3954-66. View

Cohen H, McGovern F . Renal-cell carcinoma. N Engl J Med. 2005; 353(23):2477-90. DOI: 10.1056/NEJMra043172. View

Lu Y, Hu X . C5a stimulates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation. Oncol Rep. 2014; 32(6):2817-23. DOI: 10.3892/or.2014.3489. View

Guo R, Ward P . Role of C5a in inflammatory responses. Annu Rev Immunol. 2005; 23:821-52. DOI: 10.1146/annurev.immunol.23.021704.115835. View

Eichelberg C, Junker K, Ljungberg B, Moch H . Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009; 55(4):851-63. DOI: 10.1016/j.eururo.2009.01.003. View

Zhu X, Zhang J, Zhuang P, Zhu H, Zhang W, Xiong Y . High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008; 26(16):2707-16. DOI: 10.1200/JCO.2007.15.6521. View

Escudier B, Eisen T, Porta C, Patard J, Khoo V, Algaba F . Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii65-71. DOI: 10.1093/annonc/mds227. View

Sun M, Shariat S, Cheng C, Ficarra V, Murai M, Oudard S . Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011; 60(4):644-61. DOI: 10.1016/j.eururo.2011.06.041. View

Gorter A, Meri S . Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today. 1999; 20(12):576-82. DOI: 10.1016/s0167-5699(99)01537-6. View

10.

Markiewski M, Lambris J . The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007; 171(3):715-27. PMC: 1959484. DOI: 10.2353/ajpath.2007.070166. View

11.

Jayson M, Sanders H . Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998; 51(2):203-5. DOI: 10.1016/s0090-4295(97)00506-2. View

12.

Tsui K, Shvarts O, Smith R, Figlin R, de Kernion J, Belldegrun A . Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. 2000; 163(2):426-30. DOI: 10.1016/s0022-5347(05)67892-5. View

13.

Gu J, Ding J, Lu C, Lin Z, Chu Y, Zhao G . Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 2013; 81(2):259-65. DOI: 10.1016/j.lungcan.2013.04.020. View

14.

Gabrilovich D, Ostrand-Rosenberg S, Bronte V . Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12(4):253-68. PMC: 3587148. DOI: 10.1038/nri3175. View

15.

Manthey H, Woodruff T, Taylor S, Monk P . Complement component 5a (C5a). Int J Biochem Cell Biol. 2009; 41(11):2114-7. DOI: 10.1016/j.biocel.2009.04.005. View

16.

Yang L, Parkin D, Ferlay J, Li L, Chen Y . Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005; 14(1):243-50. View

17.

Linehan W, Walther M, Zbar B . The genetic basis of cancer of the kidney. J Urol. 2003; 170(6 Pt 1):2163-72. DOI: 10.1097/01.ju.0000096060.92397.ed. View

18.

Shalapour S, Karin M . Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015; 125(9):3347-55. PMC: 4588298. DOI: 10.1172/JCI80007. View

19.

Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Staehler M . Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27(20):3312-8. DOI: 10.1200/JCO.2008.19.5511. View

20.

Nitta H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K . Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res. 2013; 19(8):2004-13. DOI: 10.1158/1078-0432.CCR-12-1204. View